To address some of the knowledge gaps, in this study we investigated the prevalence of P/LP germline variants in the multi-organ moderate-to-high penetrance cancer predisposition genes ATM, BRCA2, BRCA1, PALB2, TP53, RAD51D, RAD51C, CHEK2, MLH1, MSH2, MSH6, and PMS2 in 750 patients with GC (with early-onset and/or a family history of cancer), recruited in a multi-centre study of several high-risk countries in Latin America and Europe, such as Portugal, Spain, Colombia, and Mexico.2 This evidence concerns the gene MSH2 and cancer.